XML 68 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1
SHAREHOLDERS' EQUITY (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Oct. 10, 2018
Jan. 31, 2023
Nov. 30, 2021
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Employees Directors And Non Employees [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Weighted average fair value of stock options granted       $ 1.2 $ 0.7 $ 1.51
Aggregate intrinsic value of exercised options       $ 9 $ 0 $ 19
Employee Stock Purchase Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Ordinary shares reserved for issuance       600,000    
Offering period       five months    
Percentage of use of base salary to purchase ordinary shares       15.00%    
Percentage of fair market value of ordinary shares at time of offering       85.00%    
Options granted       0 0 158,025
2010 Share Option Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Ordinary shares reserved for issuance       14,195,152    
Ordinary shares available for issuance       891,922    
Vesting period       4 years    
Award expiration period       10 years    
Unrecognized share-based compensation expense       $ 3,602    
Unrecognized compensation cost, recognition period       2 years 6 months 21 days    
Master Clinical Agreement [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Offering price per share $ 4.95   $ 8.57333      
Issuance of shares, net, shares 2,424,243   2,332,815      
Equity investment $ 12,000   $ 20,000      
Percentage of closing price 33.00%   33.00%      
Collaborative Arrangements [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Maximum Authorized Proceeds From Issuance Of Common Stock       $ 7,788    
Issuance expenses       91    
Deferred Participation Of B M S In R And D Expenses       4,121    
Collaborative Arrangements Two [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Maximum Authorized Proceeds From Issuance Of Common Stock       14,958    
Issuance expenses       42    
Deferred Participation Of B M S In R And D Expenses       $ 5,000    
Leerink Partners LLC [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Issuance of shares, net, shares       2,905,550    
Issuance expenses       $ 548    
Proceeds from ordinary shares in offering   $ 50,000   $ 3,625